ClinicalTrials.gg
CompletedNCT02848313Updated Oct 20, 2020Results posted

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

A Phase 1 interventional study of Elamipretide in Age-Related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-10-20.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
286th of 491
40 · median 55
Started
2016
with 18 others
Phase 1
91 of 645
10 open now
Registered
349th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 286th largest by enrollment of the 491 interventional ones that give a count, is one of 19 that started in 2016, is one of 91 in phase 1, and was the 349th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, Phase 1 single-center study in approximately 40 subjects who have 1 eye with intermediate AMD, including a high-risk drusen without geographic atrophy (GA) subgroup and a noncentral GA subgroup. Eligible subjects will receive 40 mg of elamipretide administered as a once daily 1.0 mL subcutaneous injection for 12 weeks.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For this study, only 1 eye of an eligible subject will be included and designated as the study eye. However, all specified ophthalmic testing will be performed on both eyes at each time point. A potential subject must meet the following criteria to be eligible for inclusion in the study:

Intermediate AMD - noncentral GA disease group:

  1. Adults ≥ 55 years of age with 1 eye with intermediate AMD - noncentral GA.
  2. No evidence of choroidal neovascularization (active or prior history) in the study eye.
  3. Geographic atrophy may be multifocal, but the cumulative GA lesion size must be:

    1. ≥ 1.27 mm2 (approximately ≥ 0.5 DA) and ≤ 10.16 mm2 (approximately ≤ 4 DA).
    2. Must reside completely within the FAF imaging field (field 2 to 30-degree image centered on the fovea).
  4. Presence of measurable hyperautofluorescence adjacent to the discrete foci of GA.

    OR

    Intermediate AMD - high-risk drusen without GA disease group:

  5. ≥ 55 years of age with one eye with intermediate AMD - high-risk drusen without GA.
  6. High-risk drusen is defined as presence of either at least 1 large (≥ 125 µm) druse or multiple medium-size (between 63 and 124 µm) drusen.

    General (both disease groups):

  7. Able to provide and willing to comply with all study visits and examinations.
  8. Women of who are not pregnant or nursing and have a negative serum pregnancy test at screening.
  9. Best-corrected visual acuity assessed by ETDRS letters ≥ 55 letters (Snellen equivalent ≥ 20/70).
  10. Low-luminance visual acuity deficit (defined as difference between BCVA and LL visual acuity) > 5 letters.
  11. Has at least two Low-Luminance Questionnaire sub scale results, in which one of the abnormal subscales is either general dim light vision or dim light reading.
  12. The fellow eye may have intermediate AMD without noncentral GA (i.e., high-risk drusen), intermediate AMD with noncentral GA, NV AMD, or central GA. Ongoing treatment with antiangiogenic therapies in the fellow eye is allowable.
  13. No evidence of visually significant cataract OR pseudophakia without evidence of posterior capsular opacity.
  14. Sufficiently clear ocular media, adequate pupillary dilation, fixation to permit quality fundus imaging, and able to cooperate sufficiently for adequate ophthalmic visual function testing and anatomic assessment.
  15. Able to administer SC study drug solution as demonstrated at screening or able to have a care provider or appropriate designee who can administer the study drug (i.e., a capable family member or home health nursing aide).
  16. If of childbearing potential or in a relationship with a partner of childbearing potential, are able to abstain from sex or use acceptable during the study and for 3 months after dosing.

    1. For men: Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the subject. The subject also agrees to use an acceptable method of contraception should they become sexually active. Subjects must use a condom with spermicide from the date of informed consent until at least 3 months after the last dose of study drug. Periodic abstinence (e.g.calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
    2. For women: abstinence is only acceptable when it is in line with the preferred and usual lifestyle of the subject. The subject agrees to use an acceptable method of contraception should they become sexually active. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy (the vasectomy procedure must have been conducted at least 60 days before the Screening visit or confirmed via sperm analysis), barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine device or system are acceptable methods.
  17. Ability and willingness to undertake all scheduled visits and assessments.

Exclusion criteria

Exclusion Criteria:

A subject with study eye who meets any of the following criteria will be excluded from the study:

Ocular conditions - study eye

  1. Age-related macular degeneration with any evidence of central GA (i.e., involving the fovea).
  2. Atrophic retinal disease because of causes other than AMD.
  3. Presence or diagnosis of exudative AMD or choroidal neovascularization in the study eye.
  4. History of diabetic retinopathy (a history of diabetes mellitus without retinopathy is not a criterion for exclusion).
  5. Presence of vitreous hemorrhage.
  6. History of retinal detachment or macular hole (stage 3 or 4) in the study eye.
  7. Presence of macular pucker.
  8. History of uncontrolled glaucoma, defined as advanced cup-to-disc ratio > 0.7 and IOP > 25, with or without topical antihypertensive eye drops; treatment of ocular hypertension or controlled glaucoma are not criteria for exclusion.
  9. History of advanced guttae indicative of Fuchs endothelial dystrophy.
  10. Presence of visually significant cataract OR presence of significant posterior capsular opacity in the setting of Pseudophakia.
  11. Presence of significant keratopathy that would cause scattering of light or alter visual function, especially in LL conditions.
  12. Ocular incisional surgery (including cataract surgery) in the study eye within 3 months (i.e. 90 days) before Day 1.
  13. Aphakia.
  14. History of vitrectomy surgery, submacular surgery, or any vitreoretinal surgery.
  15. Prior treatment with Visudyne ® (verteporfin), external-beam radiation therapy (for intraocular conditions), or transpupillary thermotherapy.
  16. History of prophylactic subthreshold laser treatment for retinal disease.
  17. Previous intravitreal drug delivery (e.g., intravitreal injection, anti-angiogenic drugs, or device implantation) in the study eye.

    Ocular conditions - either eye

  18. Active uveitis and/or vitritis (grade trace or above) in either eye.
  19. History of idiopathic or -associated uveitis in either eye.
  20. Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.

    Systemic conditions

  21. Known to be or receiving systemic immunosuppression.
  22. Any disease or medical condition that in the opinion of the Investigator would prevent the subject from participating in the study or might confound study results.
  23. Estimated \< 30 mL/minute, by MDRD.
  24. Presence or history of allergy disease requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.

    General

  25. Participation in other drug or device clinical trials within 30 days before enrollment, or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion.
  26. History of allergy to fluorescein that is not amenable to treatment.
  27. Inability to comply with study or follow-up procedures.
  28. Inability to obtain color fundus photograph, FAF, and fluorescein angiography of sufficient quality to be analyzed and interpreted.
  29. History of allergic reaction to the investigational drug or any of its components.
  30. Current use of or likely need for any excluded medication.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Intermediate AMD - HRD without GA

    Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy \[GA\]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen. Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.

    Drug: Elamipretide

  • Experimental
    Intermediate AMD with NCGA

    Participants had 1 eye with intermediate AMD with noncentral geographic atrophy \[NCGA\]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area\[DA\]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography \[SD-OCT\]). Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.

    Drug: Elamipretide

Interventions

  • 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.

    Also known as: MTP-131; Bendavia

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA)

    Change from Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) at 4 meters, letters from Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.

    Time frame: Day 0 (Baseline to Day 7, and to Weeks 4, 8, 12, 16, 20, 24, and 28.

Secondary outcomes

  1. Change From Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA)

    Change from Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA) from Baseline (Day 0) to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.

    Time frame: Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.

  2. Change From Baseline in Mean Dark Adaptometry

    Change from Baseline in Mean Dark Adaptometry from Baseline to Week 24- at 0% 25%, 50%, 75% Bleach Level. Dark adaptometry, used to evaluate night blindness by measuring the absolute thresholds of rod sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7. Dark adaptation is the delayed recovery of light sensitivity in darkness following prior light exposure (photobleaching). The observed and change from baseline recovery scores (in minutes) for each bleach level (0%, 25%, 50%, and 75%) were summarized descriptively for each eye at each visit and were presented in a listing. Shorter recovery times are better than longer recovery times.

    Time frame: Baseline (Day 0) and Week 24

  3. Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide

    Mean percentage of treatment compliance of administration of subcutaneous elamipretide. The number of injections (diary) and vials used was used to compute % compliance over the duration of the subject's participation in the trial. Percentage can range from 0-100%, where 0% means the participant followed the correct dosing 0% of the time, and 100% compliance means the participant followed the correct dosing 100% of the time, with a higher % meaning a better outcome.

    Time frame: Baseline through Week 28

  4. Mean Number of Home Health Visits to Administer Elamipretide

    Mean Number of Home Health Visits Necessary for Participant or Caregiver to Learn How to Administer Elamipretide

    Time frame: Baseline (Day 0) through Week 24

  5. Change From Baseline in Mean Area of Geographic Atrophy by Fundus Autofluorescence

    Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.

    Time frame: Baseline (Day 0) to Week 24

  6. Change From Baseline in Mean Area of Geographic Atrophy as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)

    Change from Baseline in Mean Area of Geographic Atrophy by Sector as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at Week 24

    Time frame: Baseline to Week 24

  7. Change From Baseline in Mean Reading Acuity Test: With Standard Luminance

    Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Standard Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

    Time frame: Baseline and Weeks 4, 8, 12, 16 20, 24 and 28

  8. Change From Baseline in Mean Reading Acuity Test: Low Luminance

    Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Low Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

    Time frame: Assessed at screening, baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28

  9. Change From Baseline in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) Score Standard Luminance

    Change from baseline (Day 0) at Week 12, 24 and 28. National Eye Institute Visual Function Questionnaire-39 (VFQ-39) score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at baseline (Day 0), Week 12, Week 24 and Week 28

  10. Change From Baseline in Mean Low Luminance Questionnaire (LLQ) Score

    Change from baseline (Day 0) at Week 12, Week 24, and Week 28 in LLQ score. The LLQ is a 32-item questionnaire with six subscales related to low luminance settings: driving, mobility, extreme lighting, general dim lighting, and peripheral vision. Each question is scored on a scale ranging from 0, or maximal difficulty, to 100, or no difficulty in low luminance settings. Higher scores mean better functioning. The questions are assigned to different subscales and are averaged to generate one score per subscale. After weighting each subscale for the number of questions, the weighted subscales are averaged to generate a composite LLQ score.

    Time frame: Baseline (Day 0), Week 12, and Week 24 and Week 28

  11. Change From Baseline in Mean Mesopic Light Sensitivity

    Change from baseline in mean mesopic light sensitivity for Weeks, 4, 8, 12, 16, 20, and 24 as assessed by microperimetry for number of loci \<25dB and \<14dB. Mesopic microperimetry, used to measure retinal sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7.

    Time frame: Baseline (Day 0) and Weeks 4,8,12,16,20,and 24

  12. Change From Baseline in Mean Retinal Pigment Epithelium - Drusen Complex (RPEDC) Thickness as Measured by SD-OCT

    Change from baseline in mean retinal pigment epithelium - drusen complex (RPEDC) thickness as Measured by SD-OCT by sector at Week 24

    Time frame: Baseline (Day 0) and Week 24

  13. Change From Baseline in Mean Retinal Pigment Epithelium-Drusen Complex Volume

    Change from baseline in mean Retinal Pigment Epithelium-Drusen Complex volume at Week 24 by sector

    Time frame: Baseline (Day 0) to Week 24

07

Results

Posted Sep 21, 2020

Participant flow

Participant flow — Overall Study
MilestoneHigh-Risk Drusen (HRD)NCGA (Noncentral GA)
Started2119
Completed1815
Not completed34
Withdrew: Adverse event12
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow up10

Outcome measures

PrimaryChange From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA)

Change from Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) at 4 meters, letters from Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.

Time frame:
Day 0 (Baseline to Day 7, and to Weeks 4, 8, 12, 16, 20, 24, and 28.
Reported as:
Mean · letters
Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA)
lettersAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Day 70.810 ± 4.87460.526 ± 4.1281
Week 42.762 ± 5.57591.833 ± 5.0904
Week 81.950 ± 4.40661.556 ± 6.2987
Week 121.150 ± 5.58451.438 ± 5.4156
Week 162.789 ± 5.89332.813 ± 5.5883
Week 203.842 ± 4.14011.438 ± 5.7847
Week 243.579 ± 6.39724.600 ± 5.0681
Week 281.333 ± 10.48813.667 ± 5.8023
SecondaryChange From Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA)

Change from Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA) from Baseline (Day 0) to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.

Time frame:
Baseline to Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28.
Reported as:
Mean · letters
Change From Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA)
lettersAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Day 72.714 ± 5.33991.105 ± 8.4518
Week 42.762 ± 4.86735.000 ± 5.5413
Week 82.800 ± 6.22054.167 ± 4.2183
Week 122.150 ± 6.69864.688 ± 4.5858
Week 165.158 ± 7.31264.875 ± 5.9203
Week 205.632 ± 7.49235.438 ± 5.8875
Week 245.632 ± 7.78325.400 ± 7.8540
Week 282.556 ± 14.20953.733 ± 8.1545
SecondaryChange From Baseline in Mean Dark Adaptometry

Change from Baseline in Mean Dark Adaptometry from Baseline to Week 24- at 0% 25%, 50%, 75% Bleach Level. Dark adaptometry, used to evaluate night blindness by measuring the absolute thresholds of rod sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7. Dark adaptation is the delayed recovery of light sensitivity in darkness following prior light exposure (photobleaching). The observed and change from baseline recovery scores (in minutes) for each bleach level (0%, 25%, 50%, and 75%) were summarized descriptively for each eye at each visit and were presented in a listing. Shorter recovery times are better than longer recovery times.

Time frame:
Baseline (Day 0) and Week 24
Reported as:
Mean · minutes
Change From Baseline in Mean Dark Adaptometry
minutesAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
0% Bleach Level-11.553 ± 10.32293.543 ± 5.0140
25% Bleach Level0.409 ± 4.27988.3302 ± 0.000
50% Bleach Level0.000 ± 0.0000-3.263 ± 7.9935
75% Bleach Level1.562 ± 5.3936-3.048 ± 9.1675
SecondaryMean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide

Mean percentage of treatment compliance of administration of subcutaneous elamipretide. The number of injections (diary) and vials used was used to compute % compliance over the duration of the subject's participation in the trial. Percentage can range from 0-100%, where 0% means the participant followed the correct dosing 0% of the time, and 100% compliance means the participant followed the correct dosing 100% of the time, with a higher % meaning a better outcome.

Time frame:
Baseline through Week 28
Reported as:
Mean · % of compliance in study dosing
Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide
% of compliance in study dosingAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide98.4 ± 4.0497.3 ± 6.70
SecondaryMean Number of Home Health Visits to Administer Elamipretide

Mean Number of Home Health Visits Necessary for Participant or Caregiver to Learn How to Administer Elamipretide

Time frame:
Baseline (Day 0) through Week 24
Reported as:
Mean · visits
Mean Number of Home Health Visits to Administer Elamipretide
visitsAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Mean Number of Home Health Visits to Administer Elamipretide2.2 ± 0.542.5 ± 1.02
SecondaryChange From Baseline in Mean Area of Geographic Atrophy by Fundus Autofluorescence

Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.

Time frame:
Baseline (Day 0) to Week 24
Reported as:
Mean · mm^2
Change From Baseline in Mean Area of Geographic Atrophy by Fundus Autofluorescence
mm^2AMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Week 12—0.264 ± 0.1641
Week 24—0.503 ± 0.4914
SecondaryChange From Baseline in Mean Area of Geographic Atrophy as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)

Change from Baseline in Mean Area of Geographic Atrophy by Sector as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at Week 24

Time frame:
Baseline to Week 24
Reported as:
Mean · mm^2
Change From Baseline in Mean Area of Geographic Atrophy as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
mm^2AMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Center Sector—0.02 ± 0.048
Inner Superior—0.05 ± 0.096
Inner Nasal—0.04 ± 0.059
Inner Inferior—0.02 ± 0.073
Inner Temporal—0.05 ± 0.097
Outer Superior—0.08 ± 0.116
Outer Nasal—0.06 ± 0.114
Outer Inferior—0.05 ± 0.146
Outer Temporal—0.08 ± 0.129
Total ETDRS grid—0.45 ± 0.607
SecondaryChange From Baseline in Mean Reading Acuity Test: With Standard Luminance

Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Standard Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

Time frame:
Baseline and Weeks 4, 8, 12, 16 20, 24 and 28
Reported as:
Mean · units on a scale
Change From Baseline in Mean Reading Acuity Test: With Standard Luminance
units on a scaleAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Week 4-0.04 ± 0.121-0.03 ± 0.091
Week 8-0.08 ± 0.111-0.02 ± 0.115
Week 12-0.10 ± 0.156-0.02 ± 0.098
Week 16-0.11 ± 0.151-0.06 ± 0.115
Week 20-0.12 ± 0.126-0.01 ± 0.109
Week 24-0.11 ± 0.152-0.02 ± 0.126
Week 28-0.04 ± 0.2010.01 ± 0.173
SecondaryChange From Baseline in Mean Reading Acuity Test: Low Luminance

Change from Baseline in Mean Reading Acuity Test: Mean Critical Print Size with Low Luminance in Weeks 4, 8, 12, 16, 20, 24 and 28 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

Time frame:
Assessed at screening, baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 28
Reported as:
Mean · units on a scale
Change From Baseline in Mean Reading Acuity Test: Low Luminance
units on a scaleAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Week 4-0.11 ± 0.170-0.09 ± 0.088
Week 8-0.16 ± 0.179-0.10 ± 0.253
Week 12-0.21 ± 0.177-0.20 ± 0.236
Week 16-0.25 ± 0.209-0.16 ± 0.232
Week 20-0.29 ± 0.184-0.14 ± 0.171
Week 24-0.28 ± 0.174-0.11 ± 0.209
Week 28-0.24 ± 0.238-0.10 ± 0.194
SecondaryChange From Baseline in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) Score Standard Luminance

Change from baseline (Day 0) at Week 12, 24 and 28. National Eye Institute Visual Function Questionnaire-39 (VFQ-39) score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at baseline (Day 0), Week 12, Week 24 and Week 28
Reported as:
Mean · score on a scale
Change From Baseline in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) Score Standard Luminance
score on a scaleAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Week 12 Color Vision8.8 ± 18.6310.9 ± 20.35
Week 12 Composite7.6 ± 7.475.5 ± 8.90
Week 12 Dependency1.9 ± 10.942.0 ± 14.02
Week 12 Distance Activities7.0 ± 8.134.6 ± 12.19
Week 12 Driving10.0 ± 12.850.6 ± 13.38
Week 12 General Health1.4 ± 8.981.9 ± 9.33
Week 12 General Vision5.3 ± 11.187.2 ± 14.02
Week 12 Mental Health9.3 ± 13.799.1 ± 14.63
Week 12 Near Activities8.2 ± 10.432.4 ± 11.51
Week 12 Ocular Pain7.5 ± 20.843.1 ± 9.68
Week 12 Peripheral Vision12.5 ± 19.027.8 ± 19.83
Week 12 Role Difficulties5.9 ± 12.255.9 ± 26.37
Week 12 Social Functioning7.5 ± 8.515.2 ± 18.48
Week 24 Color Vision11.8 ± 22.6211.7 ± 26.50
Week 24 Composite9.2 ± 9.197.0 ± 9.38
Week 24 Dependency2.3 ± 14.616.7 ± 10.94
Week 24 Distance Activities8.4 ± 11.114.7 ± 16.13
Week 24 Driving14.5 ± 14.660.6 ± 10.46
Week 24 General Health-0.3 ± 9.013.3 ± 10.21
Week 24 General Vision8.7 ± 12.786.3 ± 13.69
Week 24 Mental Health9.5 ± 17.557.7 ± 9.80
Week 24 Near Activities9.8 ± 11.005.6 ± 13.84
Week 24 Ocular Pain5.9 ± 19.265.0 ± 14.02
Week 24 Peripheral Vision17.1 ± 16.7815.0 ± 18.42
Week 24 Role Difficulties6.9 ± 11.585.8 ± 17.27
Week 24 Social Functioning6.6 ± 10.965.6 ± 15.64
Week 28 Color Vision12.5 ± 17.685.0 ± 28.66
Week 28 Composite7.9 ± 14.044.3 ± 10.46
Week 28 Dependency1.7 ± 17.91-1.3 ± 20.07
Week 28 Distance Activities5.7 ± 16.927.1 ± 13.95
Week 28 Driving12.3 ± 12.540.8 ± 9.47
Week 28 General Health4.2 ± 10.184.0 ± 9.20
Week 28 General Vision8.6 ± 16.253.7 ± 12.60
Week 28 Mental Health9.4 ± 19.845.7 ± 10.50
Week 28 Near Activities6.0 ± 20.171.7 ± 12.63
Week 28 Ocular Pain7.6 ± 20.170.0 ± 14.94
Week 28 Peripheral Vision15.3 ± 21.2513.3 ± 20.85
Week 28 Role Difficulties4.2 ± 21.005.4 ± 20.03
Week 28 Social Functioning5.6 ± 17.853.3 ± 10.82
SecondaryChange From Baseline in Mean Low Luminance Questionnaire (LLQ) Score

Change from baseline (Day 0) at Week 12, Week 24, and Week 28 in LLQ score. The LLQ is a 32-item questionnaire with six subscales related to low luminance settings: driving, mobility, extreme lighting, general dim lighting, and peripheral vision. Each question is scored on a scale ranging from 0, or maximal difficulty, to 100, or no difficulty in low luminance settings. Higher scores mean better functioning. The questions are assigned to different subscales and are averaged to generate one score per subscale. After weighting each subscale for the number of questions, the weighted subscales are averaged to generate a composite LLQ score.

Time frame:
Baseline (Day 0), Week 12, and Week 24 and Week 28
Reported as:
Mean · score on a scale
Change From Baseline in Mean Low Luminance Questionnaire (LLQ) Score
score on a scaleAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Week 12 Control questions10.5 ± 15.47-2.3 ± 9.86
Week 12 Dim light reading9.7 ± 12.584.3 ± 13.05
Week 12 Driving or riding in car12.2 ± 16.413.9 ± 10.92
Week 12 General dim light vision11.9 ± 13.266.9 ± 12.62
Week 12 Light transitions and glare9.3 ± 15.076.3 ± 13.35
Week 12 Mobility6.7 ± 11.666.3 ± 10.32
Week 12 Other Activities of Daily Living (ADLs)11.5 ± 18.3610.2 ± 15.29
Week 12 Peripheral vision16.3 ± 19.493.9 ± 17.51
Week 24 Control questions7.2 ± 12.560.7 ± 12.47
Week 24 Dim light reading15.8 ± 14.347.1 ± 11.30
Week 24 Driving or riding in car16.4 ± 18.774.2 ± 14.11
Week 24 General dim light vision15.6 ± 15.177.7 ± 12.10
Week 24 Light transitions and glare17.4 ± 13.986.7 ± 13.71
Week 24 Mobility9.6 ± 20.272.8 ± 16.57
Week 24 Other Activities of Daily Living (ADLs)17.8 ± 17.9510.4 ± 20.82
Week 24 Peripheral vision17.8 ± 20.125.8 ± 24.03
Week 28 Control Questions3.2 ± 18.440.2 ± 14.25
Week 28 Dim light reading12.2 ± 19.707.1 ± 12.47
Week 28 Driving or riding in car10.8 ± 23.854.3 ± 14.34
Week 28 General dim light vision11.7 ± 19.433.3 ± 10.73
Week 28 Light transitions and glare15.0 ± 14.755.3 ± 14.07
Week 28 Mobility7.4 ± 23.02-1.1 ± 14.39
Week 28 Other Activities of Daily Living12.2 ± 23.823.8 ± 13.73
Week 28 Peripheral Vision13.9 ± 20.065.0 ± 15.53
SecondaryChange From Baseline in Mean Mesopic Light Sensitivity

Change from baseline in mean mesopic light sensitivity for Weeks, 4, 8, 12, 16, 20, and 24 as assessed by microperimetry for number of loci \<25dB and \<14dB. Mesopic microperimetry, used to measure retinal sensitivity, was performed within 14 days before Day 0 and at all in-person visits except for Day 7.

Time frame:
Baseline (Day 0) and Weeks 4,8,12,16,20,and 24
Reported as:
Mean · loci
Change From Baseline in Mean Mesopic Light Sensitivity
lociAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Number of loci <25dB Week 40.6 ± 6.080.6 ± 1.79
Number of loci <25dB Week 81.3 ± 8.210.7 ± 1.94
Number of loci <25dB Week 120.5 ± 7.870.1 ± 3.09
Number of loci <25dB Week 160.9 ± 8.560.1 ± 2.35
Number of loci <25dB Week 20-1.2 ± 5.88-0.1 ± 1.44
Number of loci <25dB Week 24-0.5 ± 8.27-0.1 ± 3.45
Number of loci <14dB Week 40.3 ± 0.31.7 ± 1.7
Number of loci <14dB Week 8-1.4 ± 3.651.7 ± 4.89
Number of loci <14dB Week 121.3 ± 10.053.2 ± 5.90
Number of loci <14dB Week 16-2.5 ± 2.381.5 ± 5.01
Number of loci <14dB Week 20-0.2 ± 6.141.5 ± 4.88
Number of loci <14dB Week 24-0.3 ± 8.303.3 ± 5.82
SecondaryChange From Baseline in Mean Retinal Pigment Epithelium - Drusen Complex (RPEDC) Thickness as Measured by SD-OCT

Change from baseline in mean retinal pigment epithelium - drusen complex (RPEDC) thickness as Measured by SD-OCT by sector at Week 24

Time frame:
Baseline (Day 0) and Week 24
Reported as:
Mean · um
Change From Baseline in Mean Retinal Pigment Epithelium - Drusen Complex (RPEDC) Thickness as Measured by SD-OCT
umAMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Center0.57 ± 5.1470.38 ± 4.137
Inner Superior1.29 ± 3.699-0.85 ± 2.389
Inner Nasal1.43 ± 3.143-0.83 ± 2.801
Inner Inferior0.72 ± 4.393-0.82 ± 3.798
Inner temporal1.00 ± 3.680-0.34 ± 2.897
Outer Superior0.34 ± 2.279-0.10 ± 1.580
Outer Nasal0.34 ± 2.301-0.09 ± 1.919
Outer Inferior-0.19 ± 2.356-0.04 ± 2.023
Outer Temporal0.25 ± 2.672-0.04 ± 1.594
Total ETDRS0.39 ± 1.885-0.25 ± 1.590
SecondaryChange From Baseline in Mean Retinal Pigment Epithelium-Drusen Complex Volume

Change from baseline in mean Retinal Pigment Epithelium-Drusen Complex volume at Week 24 by sector

Time frame:
Baseline (Day 0) to Week 24
Reported as:
Mean · mm^3
Change From Baseline in Mean Retinal Pigment Epithelium-Drusen Complex Volume
mm^3AMD-High-Risk Drusen (HRD)AMD-NCGA (Noncentral GA)
Center0.00 ± 0.0040.00 ± 0.003
Inner superior0.00 ± 0.006-0.00 ± 0.004
Inner nasal0.00 ± 0.005-0.00 ± 0.004
Inner inferior0.00 ± 0.007-0.00 ± 0.006
Inner temporal0.00 ± 0.006-0.00 ± 0.005
Outer superior0.00 ± 0.012-0.00 ± 0.008
Outer nasal0.00 ± 0.012-0.00 ± 0.010
Outer inferior-0.00 ± 0.012-0.00 ± 0.011
Outer temporal0.00 ± 0.014-0.00 ± 0.009
Total ETDRS0.01 ± 0.054-0.01 ± 0.046

Adverse events

Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High-Risk Drusen (HRD)0/21 (0%)1/21 (4.8%)21/21 (100%)
NCGA (Noncentral GA)0/19 (0%)1/19 (5.3%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventHigh-Risk Drusen (HRD)NCGA (Noncentral GA)
Urinary tract infectionInfections and infestations0/211/19
SepsisInfections and infestations0/211/19
Calculus urinaryRenal and urinary disorders1/210/19
Most frequent other events
Showing 10 of 48
Most frequent other events
EventHigh-Risk Drusen (HRD)NCGA (Noncentral GA)
Injection site pruritisGeneral disorders21/2117/19
Injection site bruisingGeneral disorders16/2113/19
Injection site erythemaGeneral disorders16/2114/19
Injection site indurationGeneral disorders16/2114/19
Injection site painGeneral disorders9/216/19
Injection site haemorrhageGeneral disorders6/217/19
Upper respiratory tract infectionInfections and infestations7/213/19
Injection site urticariaGeneral disorders5/214/19
Punctate keratitisEye disorders3/210/19
NauseaGastrointestinal disorders1/212/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)High-Risk Drusen (HRD)NCGA (Noncentral GA)Total
Mean70.9 ± 8.5476.0 ± 8.2273.3 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)High-Risk Drusen (HRD)NCGA (Noncentral GA)Total
Female131124
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)High-Risk Drusen (HRD)NCGA (Noncentral GA)Total
Hispanic or Latino112
Not Hispanic or Latino201838
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)High-Risk Drusen (HRD)NCGA (Noncentral GA)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White211940
More than one race000
Unknown or Not Reported000
Smoking Status
Smoking Status(Participants)High-Risk Drusen (HRD)NCGA (Noncentral GA)Total
Never smoker13821
Former smoker81119
Current smoker000
08

Study locations

1 site
  • Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center)
    Durham, North Carolina 27710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Mar 2018, 16 months.

Results were first posted in Sep 2020, 2 years 6 months after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 16 months is close to that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Jul 28, 2016
StartActual
Oct 28, 2016
Primary completionActual
Mar 16, 2018
CompletionActual
Apr 10, 2018
Results first posted
Sep 21, 2020
Last update
Oct 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02848313
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Oct 28, 2016
Primary completion
Mar 16, 2018
Completion
Apr 10, 2018
Results posted
Sep 21, 2020
Last update
Oct 20, 2020

Study contacts

Scott W Cousins, MD
principal investigator · Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion